Effects of low-dose mifepristone administration in two different 14-day regimens on the menstrual cycle and endometrial development:a randomized controlled trial

Contraception

Volumn 84, Issue 1, 2011, Pages 64-70

  Chen, Yuezhou ^a   Wang, Wen ^a   Zhuang, Yaling ^a   Chen, Xiuying ^a   Huang, Lili ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Endometrial contraception; Endometrial development; Endometrial receptivity; Menstrual cycle; Mifepristone

Indexed keywords

LEUKEMIA INHIBITORY FACTOR; MIFEPRISTONE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CONTRACEPTION; ENDOMETRIUM; ENDOMETRIUM BIOPSY; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LOW DRUG DOSE; LUTEAL PHASE; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; ORGANOGENESIS; OVULATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADULT; CONTRACEPTIVES, ORAL, SYNTHETIC; ENDOMETRIUM; FEMALE; HUMANS; LEUKEMIA INHIBITORY FACTOR; MENSTRUAL CYCLE; MIFEPRISTONE; OVULATION; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 79958771665     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.12.001     Document Type: Article

References (21)

1. Spitz IM, Robbins A. Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Hum Reprod Update 1998;4:584-93. (Pubitemid 29041472)
2. Spitz IM, Bardin CW. Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med 1993;329:404-12. (Pubitemid 23219347)
3. Croxatto HB, Salvatierra AM, Croxatto HD, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993;8:201-7. (Pubitemid 23092780)
4. Danielsson KG, Swahn ML, Westlund P, Johannisson E, Seppala M, Bygdeman M. Effect of low daily doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1997;12:124-31. (Pubitemid 27077612)
5. Gemzell-Danielsson K, Westlund P, Johannisson E, Swahn ML, Bygdeman M, Seppala M. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1996;11:256-64. (Pubitemid 26089170)
6. Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8:870-3. (Pubitemid 23193680)
7. Swahn ML, Bygdeman M, Cekan S, Xing S, Masironi B, Johannisson E. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod 1990;5:402-8. (Pubitemid 20346823)
8. Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update 2004;10:341-8. (Pubitemid 38997071)
9. Li L, Zhou Z, Huang L. Abnormal expression of MMP-9 and imbalance of MMP-9/TIMP-1 is associated with prolonged uterine bleeding after a medical abortion with mifepristone and misoprostol. Acta Obstet Gynecol Scand 2009;88:673-9.
10. Asch RH, Rojas FJ. The effects of RU486 on the luteal phase of the rhesus monkey. J Steroid Biochem 1985;22:227-30. (Pubitemid 15148417)
11. Schaison G, George M, Lestrat N, Reinberg A, Baulieu EE. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women. J Clin Endocrinol Metab 1985;61:484-9. (Pubitemid 15243960)
12. Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70. (Pubitemid 34084672)
13. Garcia E, Bouchard P, De Brux J, et al. Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating. J Clin Endocrinol Metab 1988;67:80-7.
14. Marions L, Hultenby K, Lindell I, Sun X, Stabi B, Gemzell DK. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002;100:65-71. (Pubitemid 34722844)
15. Gemzell-Danielsson K, Svalander P, Swahn ML, Johannisson E, Bygdeman M. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase. Hum Reprod 1994;9:2398-404.
16. Ghosh D, Sengupta J. Anti-nidatory effect of a single, early postovulatory administration of mifepristone (RU 486) in the rhesus monkey. Hum Reprod 1993;8:552-8. (Pubitemid 23116957)
17. Senturk LM, Arici A. Leukemia inhibitory factor in human reproduction. Am J Reprod Immunol 1998;39:144-51. (Pubitemid 28062286)
18. Lass A, Weiser W, Munafo A, Loumaye E. Leukemia inhibitory factor in human reproduction. Fertil Steril 2001;76:1091-6. (Pubitemid 33116368)
19. Delage G, Moreau JF, Taupin JL, et al. In-vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women. Hum Reprod 1995;10:2483-8.
20. Danielsson KG, Swahn ML, Bygdeman M. The effect of various doses of mifepristone on endometrial leukaemia inhibitory factor expression in the midluteal phase - an immunohistochemical study. Hum Reprod 1997;12:1293-7. (Pubitemid 27273562)
21. Cameron ST, Critchley HO, Buckley CH, Kelly RW, Baird DT. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertil Steril 1997;67:1046-53. (Pubitemid 27241896)